Qiagen (NYSE:QGEN) Receives $51.50 Average Target Price from Analysts

Shares of Qiagen (NYSE:QGEN) have earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $51.50.

Several research firms recently weighed in on QGEN. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 price target (down previously from $50.00) on shares of Qiagen in a report on Monday, January 6th. Jefferies Financial Group reissued a “buy” rating and issued a $54.00 target price (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $45.16 on Thursday. The stock has a market cap of $10.31 billion, a price-to-earnings ratio of 115.79, a P/E/G ratio of 3.31 and a beta of 0.37. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.44. The stock’s 50-day moving average is $44.14 and its 200 day moving average is $44.01.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of QGEN. GAMMA Investing LLC increased its holdings in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares during the period. Toronto Dominion Bank acquired a new stake in shares of Qiagen during the second quarter worth $27,000. Massmutual Trust Co. FSB ADV lifted its position in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Qiagen during the third quarter valued at $53,000. Finally, Headlands Technologies LLC raised its position in shares of Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after acquiring an additional 2,189 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.